ArticleCureus2025
Evaluation of the Short-Term Effect of Tirzepatide on Liver Fibrosis Biomarkers Stratified by the Fibrosis-3 Index (FIB-3) in Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims The primary objective of this study is to evaluate the short-term impact of tirzepatide on liver fibrosis markers, specifically the Fibrosis-3 index (FIB-3), Fibrosis-4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI), in patients with type 2 diabetes mellitus (T2DM). The secondary objective is to assess the correlations between FIB-3 and established fibrosis indices, including FIB-4 and APRI. Methods A total of 87 patients were stratified into two subgroups based on their FIB-3 score at the initiation of tirzepatide, following the FIB-3 classification: Group 1 (G1) (FIB-3 <1.5; n=68) and Group 2 (G2) (FIB-3 ≥1.5; n=19). We evaluated the changes in FIB-3, FIB-4, and APRI three months after the initiation of tirzepatide in each subgroup. Subsequently, we compared the changes (Δ) in FIB-3, FIB-4, and APRI scores across the two subgroups. Additionally, we investigated the baseline parameters and changes in these parameters correlated with Δ FIB-3. Correlation coefficients between FIB-3 and both FIB-4 and APRI were calculated. Results Only APRI exhibited a significant decrease in G1 (p=0.029), but FIB-3 (p<0.001), FIB-4 (p=0.005), and APRI (p<0.001) decreased significantly in G2. Δ FIB-3 (p=0.003), Δ FIB-4 (p=0.001), and Δ APRI (p<0.001) in G2 were significantly greater than those observed in G1. Δ FIB-3 was inversely correlated with baseline FIB-3 and positively correlated with Δ γ-glutamyl transpeptidase. FIB-3 demonstrated strong correlations with FIB-4 (r=0.81) and APRI (r=0.85). Conclusions In patients with T2DM, those with higher baseline FIB-3 values exhibited a more pronounced reduction in liver fibrosis markers during the short-term period following the initiation of tirzepatide therapy. FIB-3 exhibited robust associations with established fibrosis markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.